Literature DB >> 20393511

Affinity maturation of an anti-V antigen IgG expressed in situ through adenovirus gene delivery confers enhanced protection against Yersinia pestis challenge.

T J Van Blarcom1, C Sofer-Podesta, J Ang, J L Boyer, R G Crystal, G Georgiou.   

Abstract

Genetic transfer of neutralizing antibodies (Abs) has been shown to confer strong and persistent protection against bacterial and viral infectious agents. Although it is well established that for many exogenous neutralizing Abs increased antigen affinity correlates with protection, the effect of antigen affinity on Abs produced in situ after adenoviral gene transfer has not been examined. The mouse IgG2b monoclonal Ab, 2C12.4, recognizes the Yersinia pestis type III secretion apparatus protein, LcrV (V antigen), and confers protection in mice when administered as an IgG intraperitoneally or after genetic immunization with engineered, replication-defective serotype 5 human adenovirus (Ad). The 2C12.4 Ab was expressed as a single-chain variable fragment (scFv) in Escherichia coli and was shown to display an equilibrium dissociation constant (K(D))=3.5 nM by surface plasmon resonance analysis. The 2C12.4 scFv was subjected to random mutagenesis, and variants with increased affinity were isolated by flow cytometry using the anchored periplasmic expression bacterial display system. After a single round of mutagenesis, variants displaying up to 35-fold lower K(D) values (H8, K(D)=100 pM) were isolated. The variable domains of the H8 scFv were used to replace those of the parental 2C12.4 IgG encoded in the Ad vector, AdalphaV, giving rise to AdalphaV.H8. The two adenoviral vectors resulted in similar titers of anti-V antigen Abs 3 days after immunization, with 10(9), 10(10) or 10(11) particle units (pu). After intranasal challenge with 363 LD(50) (lethal dose, 50%) of Y. pestis CO92, 54% of the mice immunized with 10(10) pu of AdalphaV.H8 survived through the 14 day end point compared with only 15% survivors for the group immunized with AdalphaV expressing the lower-affinity 2C12.4 (P<0.04; AdalphaV versus AdalphaV.H8). These results indicate that affinity maturation of a neutralizing Ab delivered by genetic transfer may confer increased protection not only for Y. pestis challenge but also possibly for other pathogens.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20393511      PMCID: PMC3784998          DOI: 10.1038/gt.2010.42

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  40 in total

1.  Isolation of high-affinity ligand-binding proteins by periplasmic expression with cytometric screening (PECS).

Authors:  G Chen; A Hayhurst; J G Thomas; B R Harvey; B L Iverson; G Georgiou
Journal:  Nat Biotechnol       Date:  2001-06       Impact factor: 54.908

2.  Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis.

Authors:  Jim Hill; Catherine Copse; Sophie Leary; Anthony J Stagg; E Diane Williamson; Richard W Titball
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

Review 3.  Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization.

Authors:  James D Marks
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

4.  Improving biosensor analysis.

Authors:  D G Myszka
Journal:  J Mol Recognit       Date:  1999 Sep-Oct       Impact factor: 2.137

Review 5.  Molecular and physiological insights into plague transmission, virulence and etiology.

Authors:  Dongsheng Zhou; Yanping Han; Ruifu Yang
Journal:  Microbes Infect       Date:  2005-08-10       Impact factor: 2.700

6.  Recombinant vaccinia viruses expressing immunoglobulin variable regions efficiently and selectively protect mice against tumoral B-cell growth.

Authors:  S BenAmmar-Ceccoli; S Humblot; R Crouzier; B Acres; M P Kieny; D Herlyn; J L Pasquali; T Martin
Journal:  Cancer Gene Ther       Date:  2001-10       Impact factor: 5.987

7.  Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity.

Authors:  Jennifer A Maynard; Catharina B M Maassen; Stephen H Leppla; Kathleen Brasky; Jean L Patterson; Brent L Iverson; George Georgiou
Journal:  Nat Biotechnol       Date:  2002-06       Impact factor: 54.908

8.  Isolation and expression of recombinant antibody fragments to the biological warfare pathogen Brucella melitensis.

Authors:  Andrew Hayhurst; Scott Happe; Robert Mabry; Zephyr Koch; Brent L Iverson; George Georgiou
Journal:  J Immunol Methods       Date:  2003-05-01       Impact factor: 2.303

9.  Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries.

Authors:  Barrett R Harvey; George Georgiou; Andrew Hayhurst; Ki Jun Jeong; Brent L Iverson; Geoffrey K Rogers
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-14       Impact factor: 11.205

10.  In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium.

Authors:  M A Rosenfeld; K Yoshimura; B C Trapnell; K Yoneyama; E R Rosenthal; W Dalemans; M Fukayama; J Bargon; L E Stier; L Stratford-Perricaudet
Journal:  Cell       Date:  1992-01-10       Impact factor: 41.582

View more
  8 in total

Review 1.  Adenovirus: the first effective in vivo gene delivery vector.

Authors:  Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2014-01       Impact factor: 5.695

Review 2.  Plague Vaccines: Status and Future.

Authors:  Wei Sun
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

3.  Increased Fab thermoresistance via VH-targeted directed evolution.

Authors:  Kevin C Entzminger; Jennifer L Johnson; Jeongmin Hyun; Raquel L Lieberman; Jennifer A Maynard
Journal:  Protein Eng Des Sel       Date:  2015-08-16       Impact factor: 1.650

4.  Multi-Functional Characteristics of the Pseudomonas aeruginosa Type III Needle-Tip Protein, PcrV; Comparison to Orthologs in other Gram-negative Bacteria.

Authors:  Hiromi Sato; Dara W Frank
Journal:  Front Microbiol       Date:  2011-07-04       Impact factor: 5.640

Review 5.  State of play and clinical prospects of antibody gene transfer.

Authors:  Kevin Hollevoet; Paul J Declerck
Journal:  J Transl Med       Date:  2017-06-07       Impact factor: 5.531

Review 6.  Antibodies Inhibiting the Type III Secretion System of Gram-Negative Pathogenic Bacteria.

Authors:  Julia A Hotinger; Aaron E May
Journal:  Antibodies (Basel)       Date:  2020-07-27

Review 7.  Antibiotic Therapy of Plague: A Review.

Authors:  Florent Sebbane; Nadine Lemaître
Journal:  Biomolecules       Date:  2021-05-12

8.  Monoclonal antibodies recognizing the surface autolysin IspC of Listeria monocytogenes serotype 4b: epitope localization, kinetic characterization, and cross-reaction studies.

Authors:  Jennifer Ronholm; Henk van Faassen; Roger MacKenzie; Zhiyi Zhang; Xudong Cao; Min Lin
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.